AIM AIM ImmunoTech Inc

  1. Stocks
  2. Healthcare
  3. NYSEAMERICAN: AIM

Price (delayed)

$0.48

Market cap

$23.44M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.43

Enterprise value

$8.93M

AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and viral diseases, including COVID-19, the disease ...

Highlights
AIM ImmunoTech's revenue has increased by 44% YoY and by 15% QoQ
The debt has declined by 13% year-on-year and by 7% since the previous quarter
AIM ImmunoTech's gross profit has surged by 187% YoY but it has decreased by 3% QoQ
AIM ImmunoTech's gross margin has soared by 160% YoY but it has decreased by 16% from the previous quarter
AIM ImmunoTech's quick ratio has plunged by 62% YoY and by 52% from the previous quarter
AIM ImmunoTech's equity has decreased by 47% YoY and by 25% QoQ
Sector: Healthcare
Industry: Biotechnology
Website: https://aimimmuno.com/
Peers: OGN

Key stats

What are the main financial stats of AIM
Market
Shares outstanding
48.84M
Market cap
$23.44M
Enterprise value
$8.93M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
1.03
Price to sales (P/S)
120.96
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
46.27
Earnings
Revenue
$193,000
EBIT
-$20.78M
EBITDA
-$20.27M
Free cash flow
-$14.07M
Per share
EPS
-$0.43
Free cash flow per share
-$0.29
Book value per share
$0.46
Revenue per share
$0
TBVPS
$0.53
Balance sheet
Total assets
$27.86M
Total liabilities
$5.26M
Debt
$750,000
Equity
$22.6M
Working capital
$18.03M
Liquidity
Debt to equity
0.03
Current ratio
4.82
Quick ratio
4.76
Net debt/EBITDA
0.72
Margins
EBITDA margin
-10,504.7%
Gross margin
84.5%
Net margin
-10,764.2%
Operating margin
-12,150.3%
Efficiency
Return on assets
-59.6%
Return on equity
-65.9%
Return on invested capital
-224.3%
Return on capital employed
-89.8%
Return on sales
-10,764.2%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

AIM stock price

How has the AIM ImmunoTech stock price performed over time
Intraday
2.13%
1 week
11.71%
1 month
5.96%
1 year
20%
YTD
53.9%
QTD
5.49%

Financial performance

How have AIM ImmunoTech's revenue and profit performed over time
Revenue
$193,000
Gross profit
$163,000
Operating income
-$23.45M
Net income
-$20.78M
Gross margin
84.5%
Net margin
-10,764.2%
AIM ImmunoTech's gross profit has surged by 187% YoY but it has decreased by 3% QoQ
AIM ImmunoTech's gross margin has soared by 160% YoY but it has decreased by 16% from the previous quarter
AIM ImmunoTech's revenue has increased by 44% YoY and by 15% QoQ
The net margin rose by 31% year-on-year and by 7% since the previous quarter

Growth

What is AIM ImmunoTech's growth rate over time

Valuation

What is AIM ImmunoTech stock price valuation
P/E
N/A
P/B
1.03
P/S
120.96
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
46.27
The company's EPS fell by 8% QoQ
AIM ImmunoTech's equity has decreased by 47% YoY and by 25% QoQ
The P/B is 29% higher than the last 4 quarters average of 0.8 but 6% lower than the 5-year quarterly average of 1.1
AIM's P/S is 56% below its 5-year quarterly average of 276.6 and 12% below its last 4 quarters average of 136.9
AIM ImmunoTech's revenue has increased by 44% YoY and by 15% QoQ

Efficiency

How efficient is AIM ImmunoTech business performance
The return on invested capital has dropped by 93% year-on-year and by 25% since the previous quarter
The ROE has plunged by 59% YoY and by 25% from the previous quarter
AIM's ROA is down by 49% YoY and by 22% QoQ
The company's return on sales rose by 31% YoY and by 7% QoQ

Dividends

What is AIM's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for AIM.

Financial health

How did AIM ImmunoTech financials performed over time
AIM's current ratio has dropped by 66% year-on-year and by 52% since the previous quarter
AIM ImmunoTech's quick ratio has plunged by 62% YoY and by 52% from the previous quarter
The debt is 97% smaller than the equity
AIM's debt to equity has surged by 50% year-on-year
AIM ImmunoTech's equity has decreased by 47% YoY and by 25% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.